Speech and language intervention for language impairment in patients in the FTD-ALS spectrum.
Speech and language intervention for language impairment in patients in the FTD-ALS spectrum. Hell J Nucl Med. 2019 Jan-Apr;22 Suppl:133-146 Authors: Kiousi V, Arnaoutoglou M, Printza A Abstract Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease that belongs to the group of motor neuron diseases. Motor deficits like reduce in tongue strength, may coexist with cognitive deficits compatible with frontotemporal dementia (FTD), also known as frontotemporal lobar degeneration (FTLD). FTD is a neurodegenerative syndrome with two main clinical variants: behavioral (bvFTD) and language or Primary Progressive Aphasia (PPA). ALS and FTD have significant clinical and neuropathological overlapping so that for some researchers they are "the ends of the same disease spectrum". A key intervention in this patient population is the speech language therapy (SLT), a specific form of cognitive intervention, which evaluates communication skills and designs a personalized intervention plan to improve communication abilities. It has been used in patients with aphasia of different etiologies and has been shown to be effective. There is limited research in SLT interventions in patients in FTD-ALS spectrum, and the initial findings indicate success to some extent. Due to progressive neurodegeneration in FTD-ALS spectrum, the main goal of the intervention is not the complete rehabilitation of linguistic deficits but the reduction and, if poss...
Condition: Caregiver Burnout Intervention: Sponsor: HealthPartners Institute Enrolling by invitation
Dysfunction of the blood-brain barrier, allowing molecules and cells not normally present in the central nervous system to enter, is one of the features of dementia. If nothing else, this causes inflammation in the brain as the immune system is roused to try to clear out the unwanted materials. Chronic inflammation in the immune cells of the central nervous system is an important part of the progression of neurodegenerative conditions, and in Alzheimer's disease shows up after the initial accumulation of amyloid-β. This sequence of events may be due in part to amyloid-β causing blood-brain barrier dysfunction, th...
Scientists from Wake Forest Baptist Health in North Carolina looked at 14 adults with mild cognitive impairment, which increases a person's risk of developing dementia.
Crick Institute links up with drug company Merck to tackle degenerative brain disorder
ALZHEIMER ’S disease is the most common cause of dementia. The symptoms of the progressive disease can seem slight at first. A new study has provided a striking explanation for one early warning sign.
There were 344,522 emergency admissions involving dementia patients like Alan Spice (pictured) in the UK in 2017/18 - the equivalent to 944 a day and up from 257,559 cases in 2013/14.
Conclusions: The association between selective autoimmune disease and neurodegenerative disorders unified by the underlying pathology frontotemporal lobar degeneration with TDP-43–positive inclusions (FTLD-TDP) extends to C9 and FTD/MND cohorts, providing further evidence that select autoimmune inflammation may be intrinsically linked to FTLD-TDP pathophysiology.
This article is protected by copyright. All rights reserved.
Conclusion: OCs most frequently occur prior to the clinical diagnosis of FTD (in 78.3[percnt] of cases, 0 to 27 years before) and also co-occur with other psychiatric conditions like anxiety, depression and psychosis. Late-onset OCs can precede frank FTD, and thus merit further attention as an early marker of FTD.Disclosure: Dr. Santibanez has nothing to disclose. Dr. Sepehry has nothing to disclose. Dr. Feldman has received personal compensation for activities with Merck, Eli Lilly and Arena and Eisai and Genentech Banne as a member of safety and diagnostic monitoring committees. Dr. Hsiung has received research support f...